Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone
http://api.archives-ouvertes.fr/search/?fq=halId_s:hal-02267221&fl=title_s,en_title_s,docid,label_s,en_label_s,docType_s,authIdHal_s,halId_s,structId_i,uri_s,keyword_s,en_keyword_s,authLastNameFirstName_s,journalTitle_s,abstract_s,en_abstract_s,producedDate_tdate,producedDateY_i,language_s,fileMain_s&sort=publicationDate_s+desc
authors
keywords
- Bortezomib
- Immunomodulatory therapy
- Lenalidomide
- Multiple myeloma
document type
ARTabstract
Recently, phase III trials assessed a new combination of lenalidomide, bortezomib, and dexamethasone (RVD) in induction therapy in transplantation‐eligible multiple myeloma (MM) patients, before consolidation with RVD and lenalidomide maintenance. We present a retrospective study evaluating this approach with patients from the real life.
